The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Director Timothy Scannell of Insulet Corp (NASDAQ:PODD) sold 7,000 shares of the company on June 10, 2024, according to a recent SEC Filing.
ACTON, Mass., May 28, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time).